Medtronic's Resolute Efficacy On Par With Abbott's Xience In One-Year Study
This article was originally published in The Gray Sheet
Executive Summary
One-year efficacy results reported May 25 at the EuroPCR meeting in Paris could help Medtronic claim a bigger stake in the drug-eluting stent market, where Abbott and Boston Scientific have increasingly dominated
You may also be interested in...
ACC Previews Next Round Of Stent Wars: Ease-Of-Use Claims Will Be Key
The singular U.S. market dominance of the cobalt-chromium everolimus-eluting stent known as Xience V or Promus is likely to be threatened next year as two new next-generation products make their way to market.
ACC Previews Next Round Of Stent Wars: Ease-Of-Use Claims Will Be Key
The singular U.S. market dominance of the cobalt-chromium everolimus-eluting stent known as Xience V or Promus is likely to be threatened next year as two new next-generation products make their way to market.
Big Data In The Big Easy: Sapien Versus Surgery Results Get Top ACC Billing
Transcatheter aortic heart valve data, and Edwards Lifesciences' Sapien valve in particular, are set to take the spotlight at yet another major cardiology conference this weekend.